In tamoxifen-sensitive breast cancer cells, tamoxifen-ER binding events significantly overlap (93%) with those of estrogen-bound ER, and likewise, tamoxifen-bound ER requires FOXA1 for chromatin engagement and inhibitory action [38,48]. Here, FOXA1 is linked to breast carcinoma.